Reactivation of tuberculosis during temsirolimus therapy.
Coriat, Romain; Mir, Olivier; Ropert, Stanislas; Loulergue, Pierre; Billemont, Bertrand; Goldwasser, François.
Invest New Drugs
; 29(6): 1494-6, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20623161
Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers.
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.
The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.
Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions.
Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient.
Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1.
A clinical approach to solving discrepancies in therapeutic drug monitoring results for patients on sirolimus or tacrolimus: Towards personalized medicine, immunosuppression and pharmacogenomics.
Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.
Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients.
Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatment.